Search - tctmd.com

Displaying 541 - 560 of 957

Sort: Relevancy | Date

News Conference News TVT 2019

Faster and Larger Gains in Physical Function With TAVR Than With Surgery: SURTAVI

Michael O'Riordan

June 17, 2019

News Conference News TVT 2019

Transcarotid Bests Aortic/Apical for Alternative TAVR Access: TVT Registry

Shelley Wood

June 17, 2019

News Conference News TVT 2019

Vast Numbers of Severe Symptomatic AS Patients Untreated? A Plea and Some Pushback

Shelley Wood

June 14, 2019

Presentation TVT 2019

Updated PFO Closure for Cryptogenic Stroke, Migraine, and More…

Presenter: Mark Reisman

June 14, 2019

Presentation TVT 2019

Practicalities of Shared Decision-Making for Stroke Prevention: Relevance to LAA Occlusion and PFO Closure

Presenter: Megan Coylewright

June 14, 2019

Presentation TVT 2019

Operator and Institutional Requirements for PFO Closure for Secondary Prevention of Paradoxical Embolic Stroke

Presenter: Zahid Amin

June 14, 2019

Presentation TVT 2019

PFO Closure for Secondary Prevention of Paradoxical Embolic Stroke: Randomized Trial Synthesis

Presenter: Fabian Nietlispach

June 14, 2019

Presentation TVT 2019

PFO Closure for Conditions Beyond Cryptogenic Stroke

Presenter: Thomas Jones

June 14, 2019

News Conference News TVT 2019

Real-world Stroke With TAVR: TVT Registry Insights Rekindle Cerebral Protection Debate

Shelley Wood

June 13, 2019

News Conference News TVT 2019

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

Michael O'Riordan

June 13, 2019

Presentation TVT 2019

The PARTNER 3 Low-Risk Randomized Trial

Presenter: Susheel Kodali

June 13, 2019

Presentation TVT 2019

The Evolut Low-Risk Randomized Trial

Presenter: Steven Yakubov

June 13, 2019

Presentation TVT 2019

Incidence, Trends, Risk Factors, and Comparison With Surgery for Early Stroke After TAVR: Reports From PARTNER and the TVT Registry (in High- and Intermediate-Risk Patients)

Presenter: Samir Kapadia

June 13, 2019

Presentation TVT 2019

Status Updates on the Next Generation of Cerebral Protection Devices

Presenter: Giora Weisz

June 13, 2019

News Daily News

Potential Warning Signs Seen for NOAC Use After TAVR

Todd Neale

June 12, 2019

News Daily News

TAVR in End-stage Renal Disease: Increased Risk Highlights Research Gaps

Yael L. Maxwell

June 11, 2019

News Daily News

Similar Mortality, Higher Early Stroke Risks in TAVR for Bicuspid Aortic Stenosis

Michael O'Riordan

June 11, 2019

Presentation

Association Between TAVR for Bicuspid vs Tricuspid Aortic Stenosis and Mortality and Stroke

June 11, 2019

News Industry News

GORE® CARDIOFORM ASD Occluder Receives FDA Approval for the Treatment of Atrial Septal Defects

June 04, 2019

News Conference News EuroPCR 2019

Amplatzer Amulet LAA Closure Device Reduces Stroke Through 2 Years: Global Registry

Caitlin E. Cox

May 31, 2019

Advertisement

Faster and Larger Gains in Physical Function With TAVR Than With Surgery: SURTAVI

Transcarotid Bests Aortic/Apical for Alternative TAVR Access: TVT Registry

Vast Numbers of Severe Symptomatic AS Patients Untreated? A Plea and Some Pushback

Updated PFO Closure for Cryptogenic Stroke, Migraine, and More…

Practicalities of Shared Decision-Making for Stroke Prevention: Relevance to LAA Occlusion and PFO Closure

Operator and Institutional Requirements for PFO Closure for Secondary Prevention of Paradoxical Embolic Stroke

PFO Closure for Secondary Prevention of Paradoxical Embolic Stroke: Randomized Trial Synthesis

PFO Closure for Conditions Beyond Cryptogenic Stroke

Real-world Stroke With TAVR: TVT Registry Insights Rekindle Cerebral Protection Debate

PCI During or After TAVR No Riskier Than PCI Before Valve Replacement

The PARTNER 3 Low-Risk Randomized Trial

The Evolut Low-Risk Randomized Trial

Incidence, Trends, Risk Factors, and Comparison With Surgery for Early Stroke After TAVR: Reports From PARTNER and the TVT Registry (in High- and Intermediate-Risk Patients)

Status Updates on the Next Generation of Cerebral Protection Devices

Potential Warning Signs Seen for NOAC Use After TAVR

TAVR in End-stage Renal Disease: Increased Risk Highlights Research Gaps

Similar Mortality, Higher Early Stroke Risks in TAVR for Bicuspid Aortic Stenosis

Association Between TAVR for Bicuspid vs Tricuspid Aortic Stenosis and Mortality and Stroke

GORE® CARDIOFORM ASD Occluder Receives FDA Approval for the Treatment of Atrial Septal Defects

Amplatzer Amulet LAA Closure Device Reduces Stroke Through 2 Years: Global Registry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content